

APSA-ASCEPT

JOINT SCIENTIFIC MEETING
5–8 DECEMBER 2017
BRISBANE CONVENTION & EXHIBITION CENTRE

Program



Optimising medicines for optimal patient outcomes



Tuesday 5 December 2017

09:00 – 18:00	Registration desk open			
	Boulevard foyer, Brisbane Convention & Exhibition Centre			
10:00 start	ASCEPT Board meeting (10:00 – 12:30)	Council of Pharmacy Schools meeting (10:00 – 12:30)	Pharmacogenomics Workshop (10:00 – 12:00)	Workshop: Careers and Early Stage Biomedical Translation (10:00 – 16:45)
	Room: Arbour Boardroom	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1
			<p>Chair: Prof Andrew Somogyi</p> <p>Thiopurine pharmacogenetics: From classic simplicity to modern complexity Dr John Duley, The University of Queensland</p> <p>Research and education programs facilitating evidence-based clinical implementation of pharmacogenomics and precision medicine in Australia Assoc Prof Liz Milward, The University of Newcastle</p> <p>Student/ECR short presentations</p> <p>Pharmacogenomics SIG AGM</p> <p>Clinical Pharmacology Workshop (13:30 – 16:45)</p> <p>Room: Meeting room B3</p> <p>Clinical Pharmacology SIG AGM</p> <p>Clin Pharm Noir — A case-based, interactive workshop on forensic toxicology</p> <p>Can the living help the deceased? Assoc Prof Darren Roberts, NSW Poisons Information Centre, Sydney Children's Hospital Network, Westmead</p> <p>The final consult Prof Nick Buckley, The University of Sydney</p> <p>Poisoning through the ages Prof Ian Whyte, Calvary Mater Newcastle</p> <p>Education Forum (12:30 – 16:45)</p> <p>Room: Meeting room B2</p> <p>ASCEPT Education Forum AGM</p> <p>Engaging students in the digital world Dr Kirsten Staff and Dr Sheridan Gentili, University of South Australia</p> <p>Preparing educators to deal with the challenges of an ever-changing higher education environment Assoc Prof Lesley Lluka, The University of Queensland and Assoc Prof Shane Bullock, Monash University</p>	<p>Supported by</p> <p>Accelerating Australia</p> <p>Supported by MTPConnect Medicine and Pharmacy Society of Australia</p> <p>10:00 – 12:30 Overview of the life sciences industry from an Australian Perspective Dr Phil Kearney, Merck Sharp & Dohme Australia and Prof Daniel Hoyer, The University of Melbourne</p> <p>Transformational stage of the industry resulting in opportunities for biomedical entrepreneurs</p> <p>What is a biomedical entrepreneur? Prof Maree Smith, The University of Queensland and Prof Darren Kelly, The University of Melbourne</p> <p>12:30 – 13:15 Lunch</p> <p>13:15 – 16:45 What is happening in our biomedical translation ecosystem? Assoc Prof Kevin Pflieger, Harry Perkins Institute of Medical Research and University of Western Australia</p> <p>Facilitated and interactive workshop to identify the main hurdles for biomedical translation in Australia from the perspective of participants</p>
17:00 – 18:00	Conference opening and Japanese Pharmacological Society keynote address			
	Room: Boulevard Auditorium			
	Chair: Prof Dom Geraghty			
	<p>Use of "extended clearance concept" in new drug discovery and development; prediction of the effect of drug-drug interaction and pharmacogenomics on PK/PD/TD of drugs - 100</p> <p>Prof Yuichi Sugiyama, Sugiyama Laboratory, RIKEN Innovation Center, Japan</p>			
18:00 – 19:30	Welcome reception			
	Boulevard foyer, Brisbane Convention & Exhibition Centre			

Social media policy

Meeting attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's specific scientific result on any forum including social media.


We respectfully ask that if you attend a presentation where a presenter has communicated that they do not wish to have their presentation commented on in the social media environment that you adhere to this request.



If you are presenting preliminary or unpublished data, and do not wish the results to be broadcast, please use the following logo with your presentation asking the audience to refrain from posting your material. It should appear on the title slide or poster, and if you like, any slides you do not want posted or commented on, so that your audience recognises your request.



Wednesday 6 December 2017

07:30 – 18:00	Registration desk open Boulevard foyer, Brisbane Convention & Exhibition Centre			
08:30 – 09:30	APSA lecture Room: Boulevard Auditorium Chair: Dr Joe Nicolazzo Reflections and connections on a pharmacokinetic journey – 101 Prof Kevin Batty, School of Pharmacy, Curtin University			
09:30 – 10:20	Morning tea with exhibitors Poster presentations: Cardiovascular, Clinical Pharmacology, Drug Discovery, Toxicology, Pharmaceutical Science		Supported by 	APSA Council meeting Room: Meeting room B1
10:25 – 12:30	Symposium 1: Cannabinoids for patients: Getting the pharmacology right first time Supported by  Queensland Government	Symposium 2: Novel aspects of drug metabolising enzymes - structure, function and regulation Room: Meeting room B3 Chairs: Prof Ross McKinnon and Prof Peter Mackenzie	Symposium 3: Mice, modelling and post-marketing surveillance to inform medication efficacy and safety Room: Meeting room B2 Chairs: Dr Danijela Gnjidic and Assoc Prof Simon Bell	Symposium 4: Optimising teaching to enhance student outcomes Room: Meeting room B1 Chairs: Dr Lynette Fernandes and Dr Greg Maynard
10:25 – 10:50	Understanding cannabinoid clinical pharmacology in order to drive clinical studies – 102 Dr Catherine Lucas, University of Newcastle	Cytochrome P450 structure - function: Insights from molecular dynamics simulations – 107 Prof John Miners and Dr Pramod Nair, Flinders University	Preclinical models to understand the risks of single and multiple concurrent medicines in old age – 112 Dr John Mach, Kolling Institute of Medical Research; The University of Sydney	Introducing a large-scale research project for undergraduate students – 117 Assoc Prof Susan Rowland, The University of Queensland
10:50 – 11:15	Cannabinoids for patients: Comparative efficacy and toxicity in a paediatric setting – 103 Prof Noel Cranswick, Melbourne University	CYP2J2 over-expression in breast cancer cells drives tumourigenesis and anti-cancer drug resistance – 108 Prof Michael Murray, The University of Sydney	Application of pharmacometric modelling for studying drug effects – 113 Prof Carl Kirkpatrick, Monash University	Peer assessment to develop critical analysis and self-reflection in large undergraduate cohorts – 118 Dr Rosa McCarty, The University of Melbourne
11:15 – 11:40	High quality human cannabinoid analytics to drive clinical studies – 104 Dr Peter Galettis, University of Newcastle	Regulation and function of UGTs in cancer – 109 Dr Robyn Meech, Flinders University	Novel approaches in pharmacoepidemiological studies to communicate benefits and risk of medicines – 114 Dr Danijela Gnjidic, The University of Sydney	Development of interprofessional communication skills for interprofessional collaboration – 119 Dr Karen Luetsch, The University of Queensland
11:40 – 12:05	Pharmacokinetic analysis of vaporized cannabinoids through inhalation – 105 Dr Zheng Liu, University of Newcastle	Arylamine N-acetyltransferase-1: Drug metabolism and more – 110 Dr Neville Butcher, The University of Queensland	Pharmacoepidemiological studies to inform medication safety in older adults with chronic diseases and dementia – 115 Assoc Prof Simon Bell, Monash University	Student perspectives on peer assessment, feedback and team work – 120 Mr Jayden Kelly and Mr Mohammadali Taher, Monash University
12:05 – 12:30	Pharmaceutical aspects of cannabis – 106 Assoc Prof Jennifer Schneider, University of Newcastle	Sulfotransferase: Structure, function and protein-protein interactions – 111 Prof Rodney Minchin, The University of Queensland	Changing guideline recommendations on the pharmacological management of back pain – 116 Assoc Prof Christine Lin, The George Institute for Global Health	Panel discussion
12:30 – 13:25	Lunch with exhibitors Poster presentations: Cardiovascular, Clinical Pharmacology, Drug Discovery, Toxicology, Pharmaceutical Science			
	Drug Disposition and Response SIG meeting Room: Meeting room B3	Pharmacoepidemiology SIG meeting Room: Meeting room B2	APSA AGM (12:45 – 14:00) (please take lunch into room with you) Room: Meeting room B1	

13:30 – 15:30	Oral presentations 1: Drug Discovery/ Pharmaceutical Science  Room: Boulevard Auditorium Chair: Dr Lauren May	Oral presentations 2: Cardiovascular Room: Meeting room B3 Chair: Dr Tracey Gaspari	ASCEPT Gillian Shenfield Early Educator Award Room: Meeting room B2 Chair: Dr Lynette Fernandes	
	Quantification of metformin in human serum by hydrophilic interaction liquid chromatography - mass spectrometry – 121 Dr Ahmed Abdalla, University of South Australia	Cardiomyocyte ErbB4 receptors are essential for cardiac hypertrophy and growth of neonatal mice, and contribute to maintenance of cardiac function in adult hearts – 129 Dr Melissa Reichelt, The University of Queensland	Developing a new unit in a new curriculum – 137 Dr Betty Exintaris, Monash University	
	ORAI1 calcium channels in cell death during mammary gland involution – 122 Dr Felicity Davis, The University of Queensland	Comparing the anti-fibrotic effects of emerging treatments: Serelaxin and the IRAP inhibitor, HFI-419 to a clinically-used angiotensin receptor blocker and ACE inhibitor in a high salt-induced mouse model of kidney disease – 130 Mr Matthew Shen, Monash University	Oral presentations 3: Pharmacoepidemiology Room: Meeting room B2 Chair: Prof Andrew McLachlan	Oral presentations 4: Cancer theme Room: Meeting room B1 Chair: Prof Alan Boddy
14:00 – 14:15	Pre-clinical pharmacokinetic development of the hypoxia-activated cytotoxin SN36506 – 123 Dr Matthew Bull, The University of Auckland, New Zealand	Role of TRPC3 in endothelium-dependent vasodilation of rat mesenteric arteries – 131 Dr Sarah Wright, University of New South Wales	What are the predictors of persistent prescription opioid analgesic use for non-cancer pain in Australia? – 138 Mrs Samanta Lalic, Monash University	Population pharmacokinetics of carboplatin, etoposide and melphalan (CEM) in children with high-risk neuroblastoma – 144 Dr Janna Duong, The University of Sydney
14:15 – 14:30	A new high-throughput approach for investigating qPCR internalisation in real-time – 124 Dr Simon Foster, University of Copenhagen, Denmark	Targeting IRAP: A novel treatment to stabilise existing abdominal aortic aneurysms – 132 Mr Kaki Fan, Monash University	Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: An Australian population-based cohort study – 139 Ms Huah Shin Ng, University of South Australia	The novel fatty acid epoxide analogue CTU targets the mitochondrion and depletes cardiolipin to promote killing of MDA-MB-231 breast cancer cells – 145 Mr Hassan Choucair, The University of Sydney
14:30 – 14:45	CSKSSDYQC peptide conjugated N-trimethyl chitosan enhance the oral bioavailability of gemcitabine by targeting goblet cells – 125 Assoc Prof Jingyuan Wen, University of Auckland, New Zealand	Inhibition of the transient receptor potential melastatin 7 (TRPM7) channel-kinase improves cardiac function in an ex vivo model of ischaemia/reperfusion injury – 133 Dr Tamara Paravicini, RMIT University	Antithrombotic prescribing for patients with a history of atrial fibrillation: An analysis using MedicineInsight data – 140 Dr Daniel Taylor, NPS MedicineWise	The potential of MK2 inhibitors in glioblastoma therapy – 146 Assoc Prof Lenka Munoz, The University of Sydney
14:45 – 15:00	Nicotine-loaded chitosan nanoparticulate dry powder inhaler formulation for its activity – 126 Dr Nazrul Islam, Queensland University of Technology	Functional regulation of bitter taste receptors by beta2-adrenergic and M2 muscarinic acetylcholine receptors – 134 Mr Jilai Zhao, The University of Queensland	Questions from Australian public and health professionals on medication use in breastfeeding: Comparative call analysis of two national medicines call centres – 141 Dr Treasure McGuire, The University of Queensland	Induction of apoptosis in triple negative breast cancer cells by selenium derivatives – 147 Ms Jackmil Puthoor Jogy, University of Otago, New Zealand

15:00 – 15:15	Monitoring NanoBRET ligand binding to endogenous adenosine A_{2B} receptors – 127 Dr Elizabeth Johnstone, Harry Perkins Institute of Medical Research	Defining the progression of diabetic cardiomyopathy in a mouse model of type 1 diabetes – 135 Dr Miles De Blasio, Baker Heart & Diabetes institute	Prevalence of potentially inappropriate medication use in older inpatients with and without cognitive impairment: A systematic review – 142 Mr Mitchell Redston, The University of Sydney	The effect of curcumin on in vitro metabolism and predicted <i>in vivo</i> exposure of imatinib – 148 Mr Jeffry Adiwidjaja, The University of Sydney
15:15 – 15:30	Dual action calcium sensing receptor modulator, calhex231, unmasks novel mode-switching mechanism – 128 Dr Karen Gregory, Monash University	Systemic and cardiac-selective targeting of histone deacetylase 4 (HDAC4) to limit diabetic cardiomyopathy – 136 Mr Andrew Willis, Monash University	Health professionals' and researchers' opinions on conducting clinical deprescribing trials – 143 Mr Alexander Clough, The University of Sydney	Triterpenoid micellar nanoparticles for the treatment of glioblastoma: Potential inhibition of the PI3K/Akt signaling – 149 Dr Rebecca Roubin, The University of Sydney
15:30 – 15:55	Afternoon tea with exhibitors			Cardiovascular SIG meeting Room: Meeting room B3
16:00 – 18:00	Oral presentations 5: Pharmacy Practice	Oral presentations 6: Drug Disposition and Response/Pharmaceutical Science Supported by 	Oral presentations 7: Urogenital and Gastrointestinal Supported by 	Oral presentations 8: Neuro- and Behavioural Pharmacology
	Room: Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1
	Chair: Dr Petra Czarniak	Chair: Dr Andrew Crowe	Chair: Dr Michael Winder	Chair: Assoc Prof Marie Odile-Parat
16:00 – 16:15	Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study – 150 Mr Mulugeta Angamo, University of Tasmania	Troches or orally dissolving tablets for delivery of pilocarpine in treatment of xerostomia (dry mouth)? – 158 Mrs Rose Estafanos, The University of Queensland	Pulsed magnetic stimulation for persistent post-prostatectomy stress urinary incontinence: A pilot study – 166 Dr Renly Lim, University of South Australia	Morphine dosing affects development of antinociceptive tolerance and motor behavior – 174 Mr Alok Kumar Paul, University of Tasmania
16:15 – 16:30	Investigating the impact of Universal Healthcare Coverage on the practice of Indonesian Community Pharmacy: A qualitative study – 151 Mr Andi Hermansyah, The University of Sydney	Lipophilic salts of small molecule kinase inhibitors for increased oral bioavailability using lipid formulations – 159 Dr Leigh Ford, Monash University	Pharmacological effects of a jungle ginger on rat prostatic smooth muscle – 167 Ms Nguok Ngie Eunice Su, Monash University	Increased osmotic pressure promotes glioblastoma invasiveness – 175 Miss Wenjun Pu, The University of Queensland
16:30 – 16:45	Home Medicines Reviews - exploring accredited pharmacists' work processes – 152 Ms Marea Patounas, Queensland University of Technology	Triglyceride-mimetic prodrugs of testosterone significantly enhance lymphatic transport and oral bioavailability – 160 Dr Tim Quach, Monash University	Post-hospital changes in medication regimen complexity and potentially inappropriate medication use in older adults with chronic kidney disease – 168 Mr Wubshet Tesfaye, University of Tasmania	Discovering methyllycaconitine analogues specific for $\alpha_4\beta_2$ over α_7 nAChR subtypes – 176 Prof Mary Chebib, The University of Sydney
16:45 – 17:00	Adoption of the Ohio Emergency Department opioid prescribing guidelines – 153 Dr Jonathan Penm, The University of Sydney	Characterising and predicting the <i>in vivo</i> kinetics of therapeutic mesenchymal stem cells and their secretome – 161 Dr Haolu Wang, The University of Queensland	Effect of Rho-kinase inhibitors on contractility of porcine corpus cavernosum – 169 Miss Amelia Jack, Bond University	Inhibition of $\alpha_5\beta_1$ with the clinically validated small peptide ATN-161 is neuroprotective and functionally restorative in experimental stroke – 177 Ms Danielle Edwards, University of Kentucky, USA

Discover a career in health



With the widest range of health courses of any Australian university, we equip you for a career in one of the fastest growing sectors in the world.

sydney.edu.au/courses/medicine-and-health

17:00 – 17:15	Pharmacy in the community: The potential of role extension – 154 Dr Caroline Morris, University of Otago, New Zealand	Permeation of quercetin through the human epidermis – 162 Dr Azadeh Alinaghi, University of South Australia	The effects of aging on polarization in collagen sandwich-cultured hepatocytes – 170 Miss Sun Woo Kang, Anzac Research Institute	Morphine regulates cellular migration and invasion by modifying the circulating proteolytic profile in mice – 178 Miss Nan Xie, The University of Queensland
17:15 – 17:30	Just rubbish? Examining the concerns and attitudes of pharmacists to pharmaceuticals entering the environment – 155 Mrs Judith Singleton, Queensland University of Technology	Evaluation of optimised piperacillin plus tobramycin combination dosage regimens against <i>Pseudomonas aeruginosa</i> (Pa) for patients with altered pharmacokinetics via the hollow fibre infection model and mechanism-based modelling – 163 Mr Rajbharan Yadav, Monash University	Human 5-HT₃AC receptors are subtly different to 5-HT₃A receptors – 171 Prof Helen Irving, La Trobe University	Stress induced analgesia is reduced in neuropathic pain states – 179 Mr Nicholas Atwal, The University of Sydney
17:30 – 17:45	Adherence to lipid lowering medications for secondary prevention of stroke – 156 Mrs Judith Coombes, The University of Queensland; Princess Alexandra Hospital	CMF-019, the first G protein biased small molecule apelin agonist, is a vasodilator and positive inotrope <i>in vivo</i> – 164 Mr Cai Read, University of Cambridge, UK	Characterization of Na_v channels in colon-innervating dorsal root ganglion neurons in mice – 172 Ms Anelain Erickson, The University of Adelaide	Phytocannabinoid actions in an animal model of neuropathic pain – 180 Miss Jessica Falon, The University of Sydney
17:45 – 18:00	Cost-effectiveness of pharmacist management of hypertension – 157 Prof Carlo Marra, University of Otago, New Zealand	Polymer precipitation inhibitors can maintain drug supersaturation and increase <i>in vivo</i> absorption from lipid-based formulations – 165 Ms Estelle Suys, Monash University	Histamine receptor (Hrh) subtypes mediate bladder afferent sensitivity in mice – 173 Ms Ashlee Caldwell, The University of Adelaide	Nesfatin-1 suppresses feeding and induces emesis in <i>Suncus murinus</i> (House Musk Shrew) – 181 Dr Sze Wa Chan, Caritas Institute of Higher Education, Hong Kong
19:30	AAPS student dinner The Plough Inn, 29 Stanley St, South Brisbane			



apsa
Australasian Pharmaceutical Science Association

APSA Annual Conference

2–5 December 2018
University of South Australia, Adelaide

www.apsa-online.org



MONASH
University




MONASH PHARMACY AND PHARMACEUTICAL SCIENCES

Proud sponsor of
APSA-ASCEPT 2017

monash.edu/pharm

17P-1214, Nov 2017, SMC, Monash University.
CRICOS provider: Monash University 00008C,
Monash College Pty Ltd 01857J

Thursday 7 December 2017

08:00 – 17:00	Registration desk open Boulevard foyer, Brisbane Convention & Exhibition Centre			
08:30 – 09:30	British Pharmacological Society keynote address Room: Boulevard Auditorium Chair: Prof Dom Geraghty Innovations in clinical pharmacology education – 200 Dr Clare Guilding, Newcastle University Medicine Malaysia, Malaysia			
09:30 – 10:25	Morning tea with exhibitors Poster presentations: Drug Disposition and Response, Inflammation/Respiratory, Neuro- and Behavioural Pharmacology, Pharmacoepidemiology, Pharmacogenomics, Urogenital and Gastrointestinal, Pharmacy Practice, Education			
10:30 – 12:30	Symposium 5: Why is polypharmacy increasing in aged care facilities and what can we do about it? Room: Boulevard Auditorium Chair: Ms Natali Jokanovic	Symposium 6: New strategies to treat chronic inflammatory diseases Supported by  Room: Meeting room B3 Chairs: Assoc Prof Ross Vlahos and Prof Emilio Badoer	Symposium 7: Novel targets for the treatment of pain Supported by  Room: Meeting room B2 Chairs: Prof Richard Lewis and Assoc Prof Irina Vetter	Symposium 8: Improving biomolecule behaviour Room: Meeting room B1 Chair: Prof Rodney Minchin
10:30 – 11:00	Increasing polypharmacy in aged care facilities: Trends, problems and solutions – 201 Ms Natali Jokanovic, Monash University	Adipokines, cardiovascular function and brain inflammation – 205 Prof Emilio Badoer, RMIT University	Decoding spinal cord circuits to find novel targets for chronic pain – 209 Dr Wendy Imlach, Monash University	CESTEM-1 clinical trials: Using dynamin inhibitors to reverse resistance to monoclonal antibody therapy – 213 Dr Fiona Simpson, The University of Queensland
11:00 – 11:30	How is Canada addressing the increasing burden of polypharmacy? – 202 Dr Justin Turner, University of Montreal, Canada	Mineralocorticoid and estrogen receptors: Novel therapeutic targets in cardiovascular disease and stroke? – 206 Prof Chris Sobey, Latrobe University	Nav1.7 as a target for pain treatment: Therapeutic challenges and opportunities – 210 Dr Sulayman Dib-Hajj, Yale University, USA	i-bodies against the chemokine receptor CXCR4 with novel pharmacology – 214 Dr Michael Foley, La Trobe University
11:30 – 12:00	Integrating prescribing and dispensing data across primary care, hospitals and aged care: The MedView Project – 203 Mr David Freemantle, Fred IT Group	The paradox of Z-drugs in motor recovery after stroke – 207 Prof Mary Collins, The University of Sydney	GPCRs and ion channels: The cause of and solution to chronic visceral pain? – 211 Assoc Prof Stuart Brierley, Flinders University; SAHMRI	Antibody-polymer-drug conjugates for biomedical applications – 215 Dr Charlotte Williams, Commonwealth Scientific and Industrial Research Organisation (CSIRO)
12:00 – 12:30	Application of a structured approach to simplify medication regimens in residential aged care – 204 Dr Janet Sluggett, Monash University	Targeting oxidant-dependent pathways to treat cognitive dysfunction in chronic obstructive pulmonary disease – 208 Assoc Prof Ross Vlahos, RMIT University	Mechanosensors and pain – 212 Dr Kate Poole, University of New South Wales	Downsizing disulfide-rich bioactive peptides – 216 Dr Richard Clark, The University of Queensland
12:30 – 13:25	Lunch with exhibitors Poster presentations: Drug Disposition and Response, Inflammation/Respiratory, Neuro- and Behavioural Pharmacology, Pharmacoepidemiology, Pharmacogenomics, Urogenital and Gastrointestinal, Pharmacy Practice, Education		Supported by 	Toxicology SIG meeting Room: Meeting room B1

Queensland Health

Medicinal Cannabis in Queensland

The key changes are:

- The Public Health (Medicinal Cannabis) Act 2016 and subordinate Regulations
- Clinical Guidance: for the use of medicinal cannabis products in Queensland: March 2017
- Standard for security of medicinal cannabis stock: January 2017

Visit www.health.qld.gov.au/public-health/topics/medicinal-cannabis



13:30 – 15:30	Oral presentations 9: Garth McQueen student oral prize	Oral presentations 10: Clinical Pharmacology	Oral presentations 11: Pharmacy Practice	Oral presentations 12: Respiratory/Toxicology
		Supported by 		
	Room: Boulevard Auditorium Chair: Dr Tina Hinton	Room: Meeting room B3 Chair: Assoc Prof Matt Doogue	Room: Meeting room B2 Chair: Dr Carl Schneider	Room: Meeting room B1 Chairs: Emeritus Prof Roy Goldie and Dr Ian Musgrave
13:30 – 13:45	Gene delivery targeting cardiac O-GlcNAc modification limits diabetic cardiomyopathy – 217 Mr Darnel Prakoso, The Baker Heart and Diabetes, The University of Melbourne	Microdosed cocktail of apixaban, edoxaban and rivaroxaban can predict drug interaction with therapeutic doses – 225 Prof Gerd Mikus, University Hospital Heidelberg, Germany	Identifying clinical pharmacist patient prioritisation criteria – 233 Mrs Nazanin Falconer, The University of Queensland	Vale Domenico (Dom) Spina Emeritus Prof Roy Goldie, Flinders University
13:45 – 14:00	The safety of metformin in haemodiafiltration – 218 Miss Felicity Smith, University of New South Wales; St Vincent's Hospital	The influence of ABCG2 genotype on allopurinol dose predictions – 226 Dr Daniel Wright, University of Otago, New Zealand	Evaluation of a quantitative approach for analysis of semi-structured pharmacy consumer interviews – 234 Mr Ardan Mirzaei, The University of Sydney	IRAK3 modulates NFkB through its guanylate cyclase activity – 241 Ms Lubna Freihat, Monash University
14:00 – 14:15	Neuronal calcium sensor-1 (NCS-1) in the regulation of calcium homeostasis and cell death in MDA-MB-231 basal breast cancer cells – 219 Miss Alice Bong, The University of Queensland	Late onset rise of 6-MMP metabolites in inflammatory bowel disease patients on azathioprine or mercaptopurine – 227 Prof Murray Barclay, Christchurch Hospital, New Zealand	Response of community pharmacy staff to a request for an antibiotic product without a valid prescription: A simulated client study in Sri Lanka – 235 Mr Shukry Zawahir, The University of Sydney	Intranasal delivery of the TLR7 agonist, imiquimod, protects against influenza A virus-induced morbidity in mice – 242 Mr Jonathan Erlich, RMIT University
14:15 – 14:30	The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants – 220 Mr Parth Upadhyay, The University of Sydney	Minimising the functional burden of medications in older inpatients: Implementation of the Drug Burden Index – 228 Ms Rayan Nahas, Royal North Shore Hospital	What Is Polypharmacy Exactly (WIPE) – 236 Ms Nashwa Masnoon, University of South Australia	A novel endosomal NOX2 oxidase inhibitor protects against high pathogenicity influenza A virus-induced disease – 243 Ms Eunice To, RMIT University
14:30 – 14:45	An investigation of the vascular effects of Sailuotong, a standardised Chinese herbal formula, for vascular dementia – 221 Miss Seungyeon Yeon, Western Sydney University; The Science of Integrative Medicine (NICM)	A stimulation study to assess the possible contribution of measurement error in quetiapine depression trials – 229 Ms Jia Ning Careen Tan, The University of Queensland	Psychotropic medicines use in Residents And Culture: Influencing Clinical Excellence (PRACTICE) tool: A development and content validation study – 237 Miss Mouna Sawan, The University of Sydney	Localisation of polymyxin in human alveolar epithelial cells – 244 Mr Maizbha Uddin Ahmed, Monash University
14:45 – 15:00	The Medication Regimen Simplification Guide for Residential Aged Care (MRS GRACE): A novel tool to optimise medication regimens for residents of aged care facilities. – 222 Ms Esa Chen, Monash University	A multicentre open-label pharmacokinetic-pharmacodynamic study of febuxostat in patients with chronic gout – 230 Mr Bishoy Kamel, University of New South Wales; St Vincent's Hospital	"Good prescribing is a bit like good driving; everybody thinks they're a good driver." An exploratory study on the barriers and facilitators to using quality prescribing indicators (QPIs) in general practice – 238 Dr Li Shean Toh, University of Tasmania	Pharmacological characterisation of small molecule C5aR1 inhibitors in primary human macrophages – 245 Ms Xaria Li, The University of Queensland

**Accelerating
Australia**

Supported by
MTPConnect
MedTech and Pharma Growth Centre



@acceleratingaus



Connect with Us

www.acceleratingaustralia.com

Biomedical entrepreneurship courses
and early stage commercialisation support:
Connecting innovative ideas to the right expertise



15:00 – 15:15	Behavioural, pharmacologic and histologic characterisation of a rat model of mechanical low back pain – 223 Mr Thomas Park, The University of Queensland	The safety and pharmacokinetics of metformin in heart failure – 231 Mrs Gina Chowdhury, University of New South Wales; St Vincent's Hospital	Contextualised medication information is critical to treatment uptake and adherence among people living with HIV – 239 Dr Amary Mey, Griffith University	Getting under the skin – why receptor fluid choice is crucial in <i>in vitro</i> skin permeation tests – 246 Dr Ana Macedo, University of South Australia
15:15 – 15:30	Understanding the physiological role of endogenous allosteric modulators in the muscarinic acetylcholine receptors – 224 Ms Ee Von Moo, Monash University	Vignettes from hospital-level electronic prescribing data – 232 Dr Paul Chin, Canterbury District Health Board, New Zealand	A study on usual Residential Medication Management Review (RMMR) practice – 240 Mrs Leila Shafiee Hanjani, The University of Queensland	Can an educational intervention lead to a sustained reduction in gastric lavage for poisoning admissions? – 247 Dr Jacques Raubenheimer, The University of Sydney
15:30 – 15:55	Afternoon tea with exhibitors			Respiratory & Inflammation SIG meeting Room: Meeting room B1
16:00 – 17:00	ASCEPT Rand Medal Lecture Room: Boulevard Auditorium Chair: Prof Dom Geraghty Optimising medicines for optimal patient outcomes? Perhaps we need more comparative ineffectiveness research! – 248 Prof Nicholas Buckley, Sydney Medical School, The University of Sydney			
17:00 – 18:00	ASCEPT AGM Room: Boulevard Auditorium			
19:00 – 23:00	Meeting dinner Boulevard Room, Brisbane Convention & Exhibition Centre			



Ranked first in Australia by the Nature Index for life sciences (2017)



Home to more than 4,000 higher degree research students



100+ research centres

The University of Queensland has been creating change for more than a century and has maintained an international reputation for research discovery, engagement and impact.

Encouraged by a stellar record of success and the prospect of helping solve the world's great challenges, UQ people refuse to accept the status quo and aim to deliver benefits to society and the environment worldwide.

Learn more at:
research.uq.edu.au



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

Create change

CRICOS Provider Number 00025B

Department of Pharmacology and Therapeutics,
School of Biomedical Sciences

RESEARCH AND COLLABORATION OPPORTUNITIES

Join Australia's leading University

Exciting research and collaborative opportunities with industry engagement in an innovative and inclusive environment for both early career and established researchers. Current projects include:

Lung Health Research Centre

A collaboration with the Royal Melbourne Hospital fostering translational research excellence, closely aligned with patient needs to improve their lung health.

The ARC Centre for Personalised Therapeutics Technologies (CPTT)

A major focus of the newly-established ARC Centre for Personalised Therapeutics Technologies, based at the University of Melbourne, is on new applications of mechanopharmacology and organ-on-a-chip technology. It will bring together the expertise needed to transform drug screening using microfluidic environments that are mechanically appropriate, with a focus on use of human cell culture. The Centre is a National collaboration with nodes at the University of Western Australia and Monash University.

Accelerating Australia

Accelerating Australia, funded by the MTPConnect Industry Growth Centre and 21 consortium members, and in affiliation with SPARK Global, will offer training in biomedical entrepreneurship in collaboration with the CPTT. This training will support new drug discovery projects as being sought under the joint venture between University of Melbourne, Monash University and BioCurate Pty Ltd.

Australian Venom Research Unit (AVRU)





An international networked group researching national and regional venomous injury problems and providing up to date information to health networks, industry, media and the community.

Visit our website:

<http://biomedicalsciences.unimelb.edu.au/departments/pharmacology>
or contact Head of Department, Professor Daniel Hoyer
E: d.hoyer@unimelb.edu.au



Friday 8 December 2017

08:00 – 15:45	Registration desk open Boulevard foyer, Brisbane Convention & Exhibition Centre			
08:30 – 09:30	APSA Medal Oration Room: Boulevard Auditorium Chair: Prof Andrew McLachlan Colloids, carriers and collaborations: A pathway to enhanced drug delivery – 300 Prof Chris Porter, Monash Institute of Pharmaceutical Sciences (MIPS), Monash University			
09:30 – 10:25	Morning tea with exhibitors			
10:30 – 12:30	Symposium 9: Certara New Investigator Award 	Symposium 10: The blood-brain barrier: A regulator of CNS drug access and disease progression 	Symposium 11: The ethics of selling or recommending complementary medicines  	Symposium 12: APSA Early Career Researchers
	Room: Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1
	Chair: Prof Carl Kirkpatrick	Chair: Dr Joe Nicolazzo	Chair: Dr Jasmina Fejzić	Chair: Prof Kevin Batty
10:30 – 11:00	The use of oral anticoagulants in people with dementia – 301 Dr Jenni Ilomaki, Monash University	BBB permeability of molecularly-targeted anti-tumor agents: necessary for effective treatment of brain tumors – 305 Prof William Elmquist, University of Minnesota, USA	Complementary medicines, health professional responsibilities and trust – 309 Prof Eleanor Milligan, Griffith University	How to reliably measure customers' perceptions of service quality in community pharmacy – 313 Dr Stephen Carter, The University of Sydney
11:00 – 11:30	Strategies for precision use of targeted anti-cancer medicines – 302 Dr Andrew Rowland, Flinders University	Clearance of beta-amyloid is facilitated by apolipoprotein E (apoE) and circulating high-density lipoproteins (HDL) in bioengineered human vessels – 306 Prof Cheryl Wellington, University of British Columbia, Canada	What are the potential harms of complementary medicines? – 310 Dr Geraldine Moses, Mater Hospital; The University of Queensland	The safety of transdermal fentanyl initiation in Australian clinical practice – 314 Dr Natasha Gisev, University of New South Wales
11:30 – 12:00	Big data: Driving innovation for geriatric pharmacoepidemiology and pharmacovigilance research – 303 Dr Prasad Nishtala, University of Otago, New Zealand	HIV infection and Alzheimer's disease: The integral role of the blood-brain barrier – 307 Prof Michal Toborek, University of Miami, USA	Selling complementary medicines and the new Code of Ethics for Pharmacists – 311 Dr Adam La Caze, The University of Queensland	Personalized microneedle eye patches by 3D printing to treat peri-orbital wrinkles with a small peptide – 315 Dr Lifeng Kang, The University of Sydney
12:00 – 12:30	Developing the next generation of analgesics – 304 Dr Jennifer Deuis, The University of Queensland	The cerebral vascular basement membrane: A target for Alzheimer's disease and stroke – 308 Prof Gregory Bix, University of Kentucky, USA	Regulating complementary medicines and pharmacy practice – 312 Assoc Prof Laetitia Hattingh, Griffith University	The provision of enhanced and extended services in Western Australian community pharmacies – 316 Dr Petra Czarniak, Curtin University
12:30 – 13:25	Lunch with exhibitors and ASCEPT student poster finalists presentation Workshop: MedicineInsight – Big data to support health research and practice, NPS MedicineWise (please take lunch into room with you) Room: Meeting room B1			



ANNUAL SCIENTIFIC MEETING




AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS

Innovation in therapeutics:
Fundamental research to clinical impact

27–30 November 2018
 ADELAIDE CONVENTION CENTRE
www.ascept.org



13:30 – 15:00	Oral presentations 13: Drug Discovery / Pharmaceutical Science	Oral presentations 14: Clinical trainees	Oral presentations 15: Pharmacogenomics	Oral presentations 16: Education
	Supported by 			
	Room: Boulevard Auditorium	Room: Meeting room B3	Room: Meeting room B2	Room: Meeting room B1
	Chair: Dr Karen Gregory	Chair: Dr Paul Chin	Chairs: Assoc Prof Nuala Helsby and Dr Marina Junqueira Santiago	Chair: Assoc Prof Elizabeth Davis
13:30 – 13:45	Reversal of age related pseudocapillarization utilising vascular endothelial growth factor related, nitric oxide dependent drug treatments on <i>in vitro</i> liver sinusoidal endothelial cells – 317 Dr Nicholas Hunt, Anzac Research Institute, The University of Sydney	A randomised controlled trial of patient information leaflets as a medication counselling tool – 323 Dr Richard McNeill, Canterbury District Health Board, New Zealand	No significant effect of <i>CYP3A</i>, <i>ABCB1</i>, <i>POR</i> and <i>NR1I2</i> polymorphisms on acute rejection and nephrotoxicity in the first 3 months post kidney transplantation in patients receiving tacrolimus – 329 Ms Rong Hu, The University of Adelaide	Best possible medication history gamification – development and pilot study – 335 Dr Paulina Stehlik, Bond University
13:45 – 14:00	Cell-specific and biased signalling of a peptide mimetic and small molecule at the relaxin receptor RXFP1 – 318 Dr Martina Kocan, Florey Institute of Neuroscience and Mental Health	“Therapy induced” Takotsubo Cardiomyopathy: Does it matter? – 324 Dr Gao Jing Ong, Queen Elizabeth Hospital	HLA-B status leading to potential severe adverse drug reactions in Aboriginal Australians – 330 Prof Andrew Somogyi, University of Adelaide	Engaging students in learning outcomes and career relevance through a multi-dimensional, interactive map – MyCourseMap – 336 Assoc Prof Lisa Tee, Curtin University
14:00 – 14:15	Investigation of the insulin mimetic effect of <i>Teucrium polium</i> in vitro – 319 Dr Rima Caccetta, Curtin University	A physiological based pharmacokinetic model to guide dosing of ivacaftor in the presence of pharmacoenhancers – 325 Dr Angela Rowland, Flinders Medical Centre	Potential simple and multifactorial drug and gene interactions of tricyclic antidepressants in older Australians – 331 Mr Mohitosh Biswas, The University of Newcastle	“Visual thinking strategies” in early pharmacy undergraduate education can support the development of professional communication and cultural competencies – 337 Dr Trudi Aspden, University of Auckland, New Zealand
14:15 – 14:30	Measuring ligand-binding in endosomes: A signalling platform for pain transmission – 320 Dr Nicholas Veldhuis, Monash University	Evaluation of the role and impact of brain computed tomography scans in the assessment of clinically diagnosed overdose cases and an attempt to formulate a procedural framework – 326 Dr Emma Tay, St Vincent’s Hospital	Signalling modification by Single Nucleotide Polymorphisms in the third intracellular loop of the mu-opioid receptor – 332 Dr Marina Junqueira Santiago, Macquarie University	Experiences developing a pharmacology online careers portal: Evaluating impact on student career awareness – 338 Dr Barbara Kemp-Harper, Monash University
14:30 – 14:45	Mutations in the NPxxY motif stabilise different conformational states of the α_{1B}- and β_2-adrenoceptors – 321 Dr Lotten Ragnarsson, The University of Queensland	Real-time review of electronic prescribing of restricted antimicrobials - a pilot of a new antimicrobial stewardship initiative for Christchurch Hospital – 327 Dr Niall Hamilton, Canterbury District Health Board, New Zealand	<i>ABCB1</i> pharmacogenetics in Papua New Guinea HIV/AIDS patients and association with efavirenz CNS/Psychiatric adverse effects – 333 Miss Helena Van Schalkwyk, University of Adelaide	Exploring the use of a novel computer-based interactive pharmacy simulation program in university and professional pharmacy practice education – 339 Dr Kenneth Lee, University of Tasmania
14:45 – 15:00	Drug delivery to the intestinal lymphatics enhances the immunosuppressant effects of mycophenolic acid in mice – 322 Mrs Ruby Panakkal Kochappan, Monash University	Thyroid immune-related adverse events following PD-1 inhibitors for cancer: Characteristics and associations – 328 Dr Frida Djukiadmodjo, Austin Health	Interleukin genetics and not <i>COMT</i> or <i>OPRM1</i> may affect risk of persistent pain following total knee arthroplasty – 334 Dr Daniel Barratt, University of Adelaide	The journey of a prescription: An interprofessional education simulation of the patient and prescription flow through prescriber and dispenser – 340 Dr James Green, University of Otago, New Zealand
15:00 – 15:15	Comfort break			
15:15 – 15:45	Awards and meeting close			
	Room: Boulevard Auditorium			
	Chairs: Dr Joseph Nicolazzo and Prof Carl Kirkpatrick			

Thank you to our sponsors

Major meeting sponsors



Faculty of
Medicine



Key meeting sponsors



Meeting supporters



Symposium supporters



Lunch sponsor

Exhibitors



Meeting secretariat



PO Box 351 Hamilton Central Qld 4007 Australia

Phone: +61 7 3848 2100 Email: apsa-ascept2017@expertevents.com.au